This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

 
News

BeiGene News

See all News
  • November 14, 2019
    U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    Read More
  • November 12, 2019
    BeiGene Reports Third Quarter 2019 Financial Results

    BeiGene Reports Third Quarter 2019 Financial Results

    Read More
  • November 6, 2019
    BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting

    BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting

    Read More
  • November 5, 2019
    Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

    Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

    Read More
  • October 31, 2019
    BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    Read More
  • October 31, 2019
    BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    Read More
  • BeiGene Facts
  • Founded 2010
  • Listings NASDAQ: BGNE  
    HKEX: 06160
  • Internally Developed
    Clinical Candidates     6
  • Marketed
    Products
    in China     3
  • Approved
    products
    in the U.S.    1
  • Global Team 3000+
story
 

  • 2010

    • BeiGene was founded as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

  • 2012

    • Began work on an anti-PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies

  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher

  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq

  • 2018

    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations

  • 2019

    • Received first FDA approval for BRUKINSA™ (zanubrutinib)
    • Regained full global rights to tislelizumab
    2019

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

Mirati LogoMei PharmaZymeworksBioAtla LogoAmbrx Logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers